Abstract Proinflammatory cytokines are associated with age-related diseases including arthritis and heart disease. IL6 and TNF also play key roles in estrogen modulation in older women. We explored whether variation in IL6 and TNF genes influenced the risk of breast cancer in samples that differed by age group: \44 years (228 cases and 271 controls), 45-64 years (426 cases and 396 controls), and 65? years (228 cases and 239 controls). Samples were drawn from population-based case-control studies conducted in Seattle. Age-adjusted odds ratios (ORs) were calculated to evaluate the risk associated with variants in IL6, IL6R, TNF, and TNFRSF1A. There was a significantly increased risk of breast cancer associated with one or more C[T alleles at IL6 rs2069861 among subjects in the oldest age group (OR 1.8, 95% CI 1.1-2.9), but no overall increased risk of breast cancer associated with any IL6 or IL6R variants in the combined data. There were significantly elevated risks of breast cancer among women 45-64 years old associated with a UTR 5 0 flanking SNP LTA rs2009658 C[G allele (OR 1.5, 95% CI 1.1-1.9) and a nonsynonomous coding SNP TNFRSF1A rs767455 T[C allele (OR 1.3, 95% CI 1.1-1.6); these two variants were also elevated in the combined data (OR 1.3, 95% CI 1.1-1.5 and OR 1.2, 95% CI 1.1-1.4, respectively). This study supports a modest association between a variant in IL6 and breast cancer among older women and TNF-related variants and breast cancer among middle-aged women. Further evaluation of these genes in other studies is warranted.
Introduction
Established risk factors for breast cancer, such as reproductive history, age, family history, and known genetic factors, do not completely account for the high rate of agerelated increases in lifetime risk for breast cancer. Although the genesis of breast cancer is heterogeneous and incompletely understood, a role for endogenous sex hormones is clear. Additional age-related factors that may increase risk of breast cancer beyond the risk associated with hormones include cytokines associated with inflammation [33] . Inflammation-associated cytokines may modulate immune response and aid evasion of tumor surveillance for many diseases associated with aging [5, 18, 26, 29] . Further support for a role of inflammation in breast carcinogenesis comes from studies that link use of nonsteroidal anti-inflammatory medications to decreased risk of breast cancer [20] .
Although there are a large number of candidate genes associated with inflammation, we chose to focus here on two cytokines that are known to increase in the circulation with age, IL6, and TNF.
IL6 mediates cell growth and differentiation in addition to its role in immune response. It is produced by a variety of cell types including lymphoid cells, endothelial cells, fibroblasts, and adipose tissue and at sites of acute and chronic inflammation, where it signals to induce an inflammatory response that includes autocrine stimulation and upregulation of other proinflammatory cytokines. Soluble IL6 is rarely detected in young healthy adults, but is elevated in older adults, even in the absence of trauma or infection. Elevated IL6 levels have been associated with age-related diseases, such as Alzheimer's disease, diabetes, and rheumatoid arthritis. In a review of the literature, Pfeilschifter et al. [30] suggest that the decrease in estrogen after menopause is strongly tied to increased activity of proinflammatory cytokines such as IL6 and TNF. IL6 signals through the IL6 receptor, a heterodimer consisting of two membrane-bound glycoproteins; we focus here on the IL6R subunit, which is the soluble form of the cytokine.
The TNF region encompasses three pleiotropic proinflammatory cytokine genes: tumor necrosis factor (TNF) and lymphotoxin A and B (LTA and LTB) located in the class III major histocompatibility complex (MHC) region of chromosome 6. These cytokines are mainly (but not exclusively) produced by macrophages and T cells. Initially, these TNF region cytokines were noted only for their anti-tumor and cell killing activities; more recent work has additionally established them as important markers of acute and chronic inflammation. TNF stimulates estrogen synthesis through aromatase induction [31] , which could be a key source of estrogen in the postmenopausal breast, and may act as a tumor promoter. TNFRSF1A is a major receptor for TNF, and belongs to a superfamily of receptors for TNF. TNFRSF1A can activate NF-KappaB, mediate apoptosis, and regulate inflammation.
In this study we investigated whether variants in the immune-modulating cytokine genes IL6, IL6R, TNF, or TNFRSF1A contribute to the risk of breast cancer.
Methods

Study populations
Study samples were drawn from prior population-based case-control studies of invasive breast cancer conducted in the Seattle area. Eligible cases for each study were ascertained from the local SEER registry [19] , the Cancer Surveillance System (CSS), and samples were restricted to Caucasian women to limit heterogeneity by race. A brief summary of each study is presented here, and more information can be obtained from prior publications.
The first contributing study, the WISH study, was a multicenter case-control study of risk factors for earlyonset breast cancer, including oral contraceptive use, developmental history, physical activity, diet, and genetics [13, 38] . Age at diagnosis for cases included in the current study was 34-44 years of age, with diagnosis dates between 1990 and 1992. Controls were ascertained using random digit telephone dialing (RDD). Interviews were completed by the Seattle site on 642 cases and 608 controls (84 and 74% of those eligible, respectively) and blood was collected from 540 and 476 of the interviewed cases and controls. We randomly selected 228 cases and 271 controls for the current study.
The second study that contributed specimens was the Seattle site of the CARE Study, a multi-center case-control study of breast cancer in women aged 45-64 years (diagnosis years between 1994 and 1998). The study was designed to investigate the risk of breast cancer in relation to exogenous hormone use [25, 27, 39] . At the Seattle site, cases were ascertained via the CSS registry and controls were ascertained by RDD. There were 1,066 cases and 1,017 controls interviewed (with 90.4 and 89.1% interview participation at the Seattle site) and over 90% of subjects provided a blood specimen. We randomly selected 426 cases and 396 controls from the CARE study for inclusion in the current study. Sampling fractions were computed to account for over sampling within strata of age, race, and first degree family history of breast cancer as previously described [25, 39] .
The oldest group of women in this study was selected from the PACE study [23, 24] , which was designed to investigate the etiology of invasive breast cancer in women 65-79 years old (diagnosed between 1997 and 1999). There were 1,210 eligible cases and 975 (80.6%) were interviewed. Controls for the PACE study (n = 1,365) were ascertained from lists of Social Security recipients generated by the Centers for Medicare and Medicaid (CMS), and 1,007 (73.8%) of eligible women were interviewed. Cases were required to have also been listed in CMS as Social Security recipients. Blood was collected from 891 (91.4%) cases and 878 (88%) controls. For the current study we randomly selected 228 case and 239 control samples frequency-matched on age from among the Caucasian PACE study participants.
Participants in all three studies completed extensive in-person interviews and donated blood at the time of interview. Information from the CSS registry on estrogen receptor (ER) and progesterone receptor (PR) status was used to categorize tumors as luminal (ER or PR positive) or non-luminal (ER and PR negative), and histology codes were grouped as ductal (ICDO 8500), lobular (ICDO 8520), or other (ICDO 8000-8481, 8501-8510, 8521-8541, 8980).
The reference age of interest in this study is the age at diagnosis of breast cancer for cases, and controls for each study were frequency-matched to the age of the cases in 5-year age groups. A total of 882 cases and 906 controls were included in the current study.
SNP selection
We assessed variation in IL6, IL6R, TNF region, and TNFRSF1A genes using a haplotype-block tagging approach. Single nucleotide polymorphisms (SNPs) were grouped based on being in high linkage disequilibrium (LD; r 2 [ 0.80) and TagSNPs were chosen to capture the majority of common variation within each gene [4] . 
Genotyping assay
SNPs were genotyped using the Applied Biosystems SNPlex Ò system and GeneMapper software. Each 96-well plate included a mixture of cases and controls as well as positive and negative DNA assay controls. As a quality control measure, 187 blind duplicate samples were included across all plates to assess the reproducibility of the genotype calls. The laboratory personnel were blinded to all sample characteristics. All SNPs were in HardyWeinberg equilibrium when we examined the distribution of genotypes among the controls in this study.
Statistical methods
For age-specific analyses, we used logistic regression to estimate the relative risk of breast cancer associated with SNP genotypes using the odds ratio (OR) approximation, after adjusting for linear age at reference. For analyses combining the three age groups, we allowed the logisticlinear association between age and risk to be arbitrarily different from one age group to the next. Data from subjects aged 45-64 were weighted by the inverse probability of being sampled and providing a blood specimen in the CARE study (based on age, race, study site, and family history). The sampling is explained more detail in Marchbanks et al. [27] . Analyses combining the three age groups used the CARE inverse probability of sampling weights for CARE participants, and a weight of one for participants from the PACE and WISH studies.
We fit additive logistic models relating each additional copy of the minor allele to the log odds of being a case for the majority of SNPs. However, in instances when there were fewer than five minor allele carriers among cases or controls, we fit a dominant model. We used a P min permutation-test procedure with 10,000 replications to account for multiple comparisons when evaluating the significance of the most associated SNP within each gene [9] . In secondary analyses, we used logistic regression of the combined study data to examine the association between SNP genotype and breast cancer risk. We fit separate models comparing ductal cases (n = 640) and luminal cases (n = 679) to all controls after adjusting for age at reference and study, as described above.
Results
A genotyping call rate of [90% was used as a quality control filter. Of the 29 TagSNPs genotyped, 2 failed genotyping (IL6R rs4845617 and TNFRSF1A rs2229092), 6 were excluded due to \90% call rate (IL6R: rs4075015, rs6694817, rs2229238, rs8192282; TNF region: rs2239704; TNFRSF1A: rs4149572), leaving 21 SNPs for the final analysis (see Table 1 ). The genotyping calls were concordant for 99.47% of the 187 replicate pairs tested; discordance among 21 pairs ranged from 1 to 3 SNP pairs. The only SNP with 3 discordant pairs was IL6R rs4509570.
As expected, the characteristics of the cases and controls differ markedly by age group (Table 2) . For all case and control subjects, body mass index (BMI) was lowest in the youngest age group, and number of prior pregnancies was highest in the oldest age group. Overall, the youngest age group had the highest percentage of control women without a family history of breast cancer. Tumor characteristics also differed by age group, with the highest proportion of luminal tumors found in the oldest age group and the highest proportion of ductal tumors in the youngest age group.
In the primary analyses, each SNP was examined separately by age group and then in all ages combined (Table 3) . Among the oldest group of women there was a significant increased risk of breast cancer associated with C[T IL6 rs2069861 (OR 1.8, 95% CI 1.1-2.9) and a marginally decreased risk of breast cancer associated with C[T IL6 rs2069849 (OR 0.4, 95% CI 0.2-1.0). There were no significant associations with IL6R variants, although we observed a marginally decreased risk of breast cancer associated with C[G IL6R rs4509570 (OR 0.7, 95% CI 0.5-1.0) among the youngest women. No association was observed between the widely studied SNP IL6 promoter SNP rs1800795 (alias -174) and breast cancer. No SNP in IL6 or IL6R survived the P min test for multiple comparisons; however, the strongest evidence of association between IL6 and breast cancer was found in the oldest age group of women (P = 0.09).
In the TNF region on chromosome 6, which contains the TNF, LTA, and LTB genes, we found an increased risk for breast cancer with C[G allele in LTA rs2009658 (OR 1.5, 95% CI 1.1-1.9) among women 45-64 years old. This variant was also associated with increased risk in the aggregate across all women aged 35-79 years old (OR 1.3, 95% CI 1.1-1.5). In the TNF receptor gene TNFRSF1A, the T[C allele rs767455 was associated with a significantly increased risk of breast cancer in middle-aged women (OR 1.3, 95% CI 1.1-1.6) and in women of all ages combined (OR 1.2, 95% CI 1.1-1.4). The overall P min test for the TNFRSF1A gene in the combined age groups data was significant (P = 0.01).
In Table 4 we examined the association between genetic variation in our SNPs and selected breast cancer subtypes, specifically those with ductal histology (n = 640) or luminal tumor markers (ER? or PR?, n = 679). The above findings were similar in these two large subgroups.
Discussion
We found increased risks of breast cancer associated with minor alleles in TNF-family variants LTA rs2009568 (OR 1.3, 95% CI 1.1-1.5) and TNFRSF1A rs767455 (OR 1.2, 95% CI 1.1-1.4) among all age groups and a marginally increased risk of breast cancer associated with IL6 rs2069861 among women 65-79 years old (OR 1.8, 95% CI 1.1-2.9). The associations for the TNF family SNPs were similar when the case group was restricted to women whose tumors had ductal histology or hormone markers consistent with luminal breast cancer. Associations between these TNF gene family variants and breast cancer risk have not been previously reported. Our TNF findings may point to risk of breast cancer associated with these gene variants or variants with which they are in linkage. We found little evidence of variability in relative risk of breast cancer across age groups at diagnosis.
Location of the TNF region between highly polymorphic human leukocyte antigen (HLA) class I and class II genes, which are important in immune surveillance, is intriguing. Linkage disequilibrium between TNF and HLA class I and II genes contributes to formation of haplotypes or stable combinations in this highly polymorphic region of the genome [8, 11] . It remains to be determined if LTA rs2009658 in the TNF region is carried with any HLA haplotypes which may be associated with breast cancer. The only well-powered study to examine this question [7] Although no genome-wide association studies (GWAS) of breast cancer has generated evidence of breast cancer risk associated with variants in IL6 or TNF genes, the potential relationship warrants consideration. IL6 and TNF stimulate conversion of estrone to estradiol [1, 10] .
Through this pathway, both cytokines may contribute to initiation of tumor development, from the very earliest stages of disease, or promote growth of established disease [2, 6] . Over the course of many years, and likely combined with the effects of other genetic factors and the cumulative effects of hormonal and environmental exposures, a proinflammatory cytokine milieu may favor the development of breast cancer in older women. Thus, we hypothesized that common variants in the proinflammatory cytokines a Proportions for age 45-64 weighted using inverse probability of sampling weights from CARE IL6 and TNF, or their receptors, may be associated with incomplete penetrance and low relative risk, which may make them difficult to detect in a GWAS. A 2007 candidate gene study by Gaudet et al. [16] used a TagSNP approach similar to ours when they evaluated the role of variation in TNF region genes in two casecontrol studies conducted in the USA and Poland. They found a marginally significant association between risk of breast cancer and the G[A allele of a TNF promoter SNP, rs361525. In a larger follow-up study of 30,000 cases and 30,000 controls, there was no evidence of association of rs361525 with risk (OR 1.00, 95% CI 0.95-1.06), so that, to date, there has been little evidence for a relationship between this SNP and breast cancer risk [17] . In the current study, TNF rs3093662 was evaluated; it tags the same signal as TNF rs361525 (r 2 = 1.0). We saw no evidence that genetic variation in this LD block was associated with risk in the age-specific studies or the combined study.
The minor allele of the TNF promoter SNP rs1800629 (alias -308) was not related to breast cancer risk in a candidate SNP study of 84 breast cancer patients and 110 control women conducted in Italy [3, 34] or in the larger Dutch HLA study described above [7] . The current study supports these finding. However, in a recently published meta-analysis that included 13 studies of TNF variants and breast cancer risk [35] , the G[A allele of TNF rs1800629 was associated with decreased risk of breast cancer (OR 0.9, 95% CI 0.879-0.978) in Caucasians; further, the AA genotype may be a risk factor for increased breast cancer risk in Africans.
We also examined the risk of breast cancer associated with variants in IL6 and IL6R. There was a significantly increased risk of breast cancer associated with allele C[T at IL6 rs2069861 (OR 1.8, 95% CI 1.1-2.9) in the oldest group of women. This variant is in the 3 0 region near the IL6 gene and has not been reported to be associated with breast cancer in other studies. Variation in 3 0 UTR regions may affect binding site of miRNA and influence gene transcription, as was previously shown for IL1A [15] . We examined whether the IL6 rs2069861 variant is a target binding site for miRNAs by searching TargetScanHuman 5.1 database (www. targetscan.org), but did not find any miRNAs targeting this SNP region. In another recent study of IL6 polymorphisms, including rs2069861, there was no difference in plasma levels of IL6 by any of eight SNPs in IL6 among women 30-55 years old from the Nurses Health study [32] . However, it may be of interest to examine IL6 plasma levels and genotype association in older women, since IL6 and other pro-inflammatory marker levels increase with age [14] .
Conflicting results of association of IL6 promoter variant rs1800795 with breast cancer have been reported. In an Australian case-only study [22] of 256 breast cancer patients, homozygous carriers of the variant allele had higher-grade breast tumors. However, in a UK study of 129 breast cancer patients and 263 organ donor controls, this variant was not associated with case-control difference in breast cancer risk [36] . Another larger study of 269 cases and 227 controls conducted in European Caucasians described an increased risk of breast cancer associated with the IL6 rs1800795 (OR 1.5, 95% CI 0.4-1.9 for GC and OR 2.0, 95% CI 1.1-3.6 for CC) [21] . The current study did not detect an increased risk of breast cancer associated with this IL6 promoter SNP.
Some limitations of this study should be noted. They include a relatively small sample size for a study of genetic variation. Since some variants likely increase the risk of breast cancer with low penetrance, we may have missed associations that do exist because of our small sample size. This size limitation was potentially made more important by our separate examination of the associations in the three age-specific populations included in this study; this was mitigated by our finding that the significant estimates from the age-specific populations were reflected in the estimates for all populations combined. Another limitation is that some of the variation in the studied genes was missed either due to assay failure, probe failure, or that a specific type of variant (for example, one in a repeat region or a copy number variation) was not detectable on the platform. This problem was particularly acute for IL6R, for which only 3 of the 8 SNPs were successfully genotyped. Future studies will be able to address these limitations by including more samples and using multiple platforms or resequencing to comprehensively cover the genetic variation for each gene.
The strength of this study is that each age group we studies showed a distribution of known risk factors for breast cancer consistent with that shown in other studies. Also, the TagSNP approach to candidate genes can comprehensively address signal variation across the genes and suggest functional roles that an individual SNP might play. LTA rs2009658, for example, is an intronic SNP located near the UTR at the 5 0 end of the LTA gene, which may influence the level of gene expression for LTA. The other significant association in this study, TNFRSF1A rs767455 is a synonymous coding SNP, Pro12Pro. Despite this synonymous change, a clinical series of Japanese Crohn's disease patients suggested that carriers of the G allele are refractory to treatment for with a monoclonal antibody directed at TNF [28] .
Prior studies have implicated IL6 and TNF-region genes a wide variety of diseases including cardiovascular disease, diabetes, and cancer [12, 37, 40] . In this study we have followed up on two hypotheses: (1) that cancer may develop from a long-term proinflammatory response [5] and (2) the common disease, common variant hypothesis. This study suggests that variation in the immune- Table 3 Risk of breast cancer associated with SNPs in IL6, IL6R, TNF region (TNF and LTA), and TNFRSF1A by age group and across studies Age 45-64 Age 65-74 Overall modulating cytokine TNF and its main receptor TNFRSF1A or genes in linkage with them may be related to the risk of breast cancer, but fails to provide strong evidence that variation in the proinflammatory cytokine IL6 and the IL6R subunit were related to breast cancer risk.
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